Today: 20 May 2026
Browse Category

NYSE:TEVA 1 November 2025 - 29 April 2026

Teva Stock Jumps As Branded Drugs Start Carrying The Old Generics Giant

Teva Stock Jumps As Branded Drugs Start Carrying The Old Generics Giant

Teva reported first-quarter adjusted earnings of 53 cents per share on $3.98 billion revenue, beating estimates as sales of Austedo, Ajovy, and Uzedy climbed. Shares jumped 11% in New York trading. The company agreed to buy Emalex Biosciences for $700 million upfront, adding a late-stage Tourette syndrome drug candidate. Global generics revenue fell 16% amid increased competition.
29 April 2026
··
Teva stock jumps after $500 million Royalty Pharma deal as investors eye JPM update

Teva stock jumps after $500 million Royalty Pharma deal as investors eye JPM update

Teva shares rose about 4% to $33.29 after announcing a funding deal with Royalty Pharma worth up to $500 million for its experimental vitiligo drug. An SEC filing previewed Teva’s 2025 outlook, including projected revenue of $16.8–$17.0 billion and adjusted EBITDA of $4.8–$5.0 billion. Investors await more details at Tuesday’s J.P. Morgan Healthcare Conference.
12 January 2026
··
Teva Stock News on Dec. 24, 2025: TEVA Rallies on S&P Credit Upgrade, $40 Price Target Hike, and Fresh Pipeline Catalysts

Teva Stock News on Dec. 24, 2025: TEVA Rallies on S&P Credit Upgrade, $40 Price Target Hike, and Fresh Pipeline Catalysts

Teva shares closed at $31.54 on Dec. 23, up 28% since Nov. 5, after S&P Global Ratings upgraded the company’s credit to ‘BB+’ on improved deleveraging. The stock traded near $31.93 pre-market Dec. 24. Analysts, including Piper Sandler, have raised price targets as Teva’s pipeline and biosimilars schedule gains clarity. Investors remain alert to pricing and patent risks.
24 December 2025
··
Teva Pharmaceutical Industries (TEVA) Stock: FDA Filing, Analyst Upgrades and 2026–27 Outlook on December 10, 2025

Teva Pharmaceutical Industries (TEVA) Stock: FDA Filing, Analyst Upgrades and 2026–27 Outlook on December 10, 2025

Teva shares traded near $29, close to 52-week highs, after filing a new FDA application for a once-monthly schizophrenia drug and receiving analyst upgrades. Market cap stands at about $32–33 billion. The company reported improved debt ratios and expects consensus 2025 EPS of $2.70. Technical indicators show the stock as overbought but still in an uptrend.
10 December 2025
··
Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors

Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors

Teva Pharmaceutical reported Q3 2025 adjusted EPS of $0.78 on $4.48 billion revenue, beating estimates and sending shares up 10–11% to a new 52-week high. The company raised 2025 guidance, citing strong sales of Austedo and other branded drugs, and Fitch upgraded its credit rating in May. Debt fell to $16.79 billion. Teva’s forward P/E remains below industry averages despite the stock’s sharp recovery.
5 November 2025
···
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 01.11.2025

WTI and RBOB futures rose Friday as traders weighed possible U.S. strikes on Venezuela, Russian energy sanctions, and OPEC+ production plans. Gains were limited by a stronger dollar and weak China PMI. Teva shares jumped 8.1% last week amid DCF-based undervaluation signals. MKS Instruments closed at $143.71, near its estimated fair value, after a 53% three-month rally.
1 November 2025
··

Stock Market Today

  • iPower Inc. Implements 1-for-8 Reverse Stock Split to Maintain Nasdaq Listing
    May 20, 2026, 12:50 AM EDT. iPower Inc. (Nasdaq: IPW) announced a 1-for-8 reverse stock split effective May 22, 2026, aimed at increasing its share price to meet Nasdaq's minimum bid price requirements. The move will consolidate every eight shares into one, reducing outstanding shares from approximately 5.29 million to about 661,000. Shareholders will receive cash for any fractional shares. The split was approved by iPower's board and stockholders and will not change the ticker symbol "IPW." The reverse split intends to keep iPower compliant with Nasdaq Capital Market listing rules while supporting the company's broader growth strategy in supply chain tech and crypto-related services.

Latest articles

Wall Street Hit by Yield Jolt With Nvidia Up Next

Wall Street Hit by Yield Jolt With Nvidia Up Next

20 May 2026
U.S. stock ETFs remained lower late Tuesday after Wall Street’s main indexes fell for a third straight session, pressured by rising Treasury yields and caution ahead of Nvidia’s earnings. The SPDR S&P 500 ETF dropped 0.7% to $733.73. The 10-year Treasury yield hit 4.687%, its highest since January 2025, before easing. Nvidia shares slipped 0.7% after hours, with traders bracing for a major move post-earnings.
Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

20 May 2026
Viavi Solutions shares dropped 7.1% in after-hours trading Tuesday after the company announced a $500 million public stock offering aimed at repaying debt. The offering, unveiled just after the Nasdaq close, could add roughly 10.1 million new shares. Viavi plans to use proceeds to pay down a $450 million loan. Total debt would fall to $650 million, according to a preliminary SEC filing.
Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

20 May 2026
Analog Devices agreed to acquire Empower Semiconductor for $1.5 billion in cash, sending ADI shares up 1.36% to $419.95 in after-hours trading after closing down 1.02%. The deal, approved by both boards, is expected to close in the second half of 2026 pending regulatory review. Empower CEO Tim Phillips will continue to lead integrated voltage regulator work after the merger.
Go toTop